Aliada Therapeutics

Despite notable advancements in Alzheimer’s disease treatment during the last five years, the therapeutic area remains a complex and uncertain area for drug developers. Approvals for the first disease

Biopharma merger and acquisition value for the fourth quarter of 2024 reached $9.4bn from 34 transactions, 15 of which had disclosed values. At the top was H. Lundbeck’s $2.6bn purchase of publicly tr

Although 2024 got off to a promising start with a busy first quarter, the fourth quarter marked the third consecutive quarter of declining biopharma merger-and-acquisition valuation. Evaluate reported

Since its inception in 2013, AbbVie has had a consistent sales and earnings story – its top-selling drug, and at times topping the entire industry, has been the anti-TNF therapeutic Humira (adalimumab